|
2.13 ETIOLOGIE - NDMA
|
|
|
|
2.14 ETIOLOGIE - TALC
|
|
|
|
|
3.4 CHIMIOPRÉVENTION
|
|
|
|
4.1 DÉP., DIAG. & PRONO. - PROSTATE
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
|
5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
Lung cancer immunotherapy gets initial ‘no’ for NHS in England [Cancer Research UK]
|
|
|
|
|
|
Adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy drugs has been shown to give patients more time before their cancer gets bigger and can improve survival. But NICE concluded there wasn’t enough evidence that these benefits are sustained in the long run, making it hard to say if the drug would be cost effective.
|
|
|
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find [STAT]
|
|
|
|
|
|
In 2016, the biotech billionaire Dr. Patrick Soon-Shiong set himself a deadline: By 2020, he would transform the fight against cancer. Four years later, independent medical researchers say they’ve heard virtual radio silence from Soon-Shiong’s initiative. And a review by STAT of clinical trial listings, research presentations, and press releases suggests the effort has fallen far short of its major goals.
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
Steepest decline in US cancer mortality ever recorded, study finds [EndPoints]
|
|
|
|
|
|
Peter Bach, director of Memorial Sloan Kettering’s center for health policy and outcomes, took issue with attributing the decline in cancer mortality to new medicines in the study led by ACS’ Rebecca Siegel. The study does not test this hypothesis, the renowned researcher and epidemiologist wrote on Twitter. “Epidemiology may be opaque but it is not opinion.”
|
|
|
|
|
|
|
|
|
|